Conference Call and Webcast at 8:30 AM Eastern Time Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com. About PAVmed PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics (Nasdaq: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the Eso ...

Mobile-health Network Solutions Introduces AI Checker, Proprietary System That Critiques Quality of Doctors' Telehealth Notes 'Major Step' in the Development of AI Doctor July 31, 2025 8:00 AM EDT | Source: Mobile-health Network Solutions This process, according to the Company, yields better care for patients, reduces audit risk, and provides superior documentation for practitioners. Furthermore, said co-founder and co-CEO Dr. Siaw Tung Yeng, the system represents "a major step and foundational building blo ...

PHOENIX, July 30, 2025 /PRNewswire/ -- Trinity Capital Inc. (Nasdaq: TRIN) (the "Company"), a leading alternative asset manager, today announced the commitment of $20 million in growth capital to b.well Connected Health ("b.well"). About Trinity Capital Inc. Trinity Capital Inc. (NASDAQ: TRIN) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized gro ...

Core Insights - OptimizeRx (OPRX) reported a strong first-quarter 2025 performance, with revenues increasing by 11% year-over-year to $21.9 million and adjusted EBITDA reaching $1.5 million, indicating solid financial health [1][9] - The company's growth is increasingly dependent on the adoption of its proprietary digital health tools, particularly the Dynamic Audience Activation Platform (DAAP), which enhances engagement for pharmaceutical clients [2][5] Financial Performance - OPRX's revenues for Q1 2025 were $21.9 million, reflecting an 11% increase from the previous year, while adjusted EBITDA turned positive at $1.5 million [1][9] - Over 5% of projected annual revenues have transitioned to a subscription-based model, which is expected to enhance margin potential and revenue visibility [3][9] Strategic Initiatives - The DAAP platform allows for real-time patient identification and targeted messaging, claiming a return on investment (ROI) exceeding 10:1 and a 25% increase in script lift for active programs [2][5] - OPRX is shifting towards a subscription-based revenue model, which is scalable and offers higher margins, with the potential for multi-year contracts to further strengthen recurring revenue streams [3][5] Competitive Landscape - The digital health sector is highly competitive, and while current client engagement is strong, future regulatory changes and economic constraints on pharmaceutical marketing budgets could impact long-term growth [4] - OPRX's technology and strategic positioning align well with the evolving needs of pharmaceutical commercialization, suggesting potential for sustained growth if subscription base and gross margins improve [5] Peer Performance - Health Catalyst (HCAT) reported Q1 2025 revenues of $79.4 million, a 6.3% year-over-year increase, with a narrowed adjusted EBITDA loss of $6.3 million, indicating strong customer retention and growth potential [6] - HealthStream (HSTM) saw Q1 2025 revenues of $73.5 million, up 1% year-over-year, with a notable multi-year deal contributing to its SaaS product growth despite macroeconomic challenges [7][8] Valuation Metrics - OPRX's stock has surged 186.9% year-to-date, significantly outperforming the industry average growth of 18.3% [12] - The forward 12-month price-to-sales (P/S) ratio for OPRX is 2.32X, lower than the industry average of 8.88X and its five-year median of 3.56X, indicating potential undervaluation [12]

Core Insights - Mobile-health Network Solutions (MNDR) has been awarded the 2025 Brands For Good Distinction Award in the category of Technology For Good, recognizing its contributions to social and environmental challenges [1][2] - The award ceremony took place on July 23, 2025, in Singapore, celebrating 41 companies from 80 nominations, highlighting the significance of technology in addressing societal issues [2][3] - MNDR's co-CEO, Dr. Siaw Tung Yeng, emphasized the company's commitment to improving healthcare accessibility through AI technology, which has been integrated into three innovative products in 2025 [4][7] Product Innovations - The first product, AI Agent, launched in January 2025, aims to reduce administrative burdens on healthcare providers and enhance workflow efficiency [4] - The second product, AI Notes, introduced in March 2025, automates the documentation process by capturing doctor-patient conversations and generating structured clinical notes in real-time [5] - The third product, AI Checker, deployed earlier this month, provides immediate feedback on the quality of doctors' consultations by evaluating notes against the QNOTE framework, a recognized medical standard [6] Company Overview - Mobile-health Network Solutions is a leading AI-powered digital health platform based in Singapore, with operations across Southeast Asia and plans for expansion into the US [9] - The company's mission is to make healthcare accessible, intelligent, and human through technology, providing telemedicine and AI-driven health tools [10]

Financial Data and Key Metrics Changes - The company reported a record quarterly cash receipts of AUD 22.4 million, contributing to a positive operating cash flow of AUD 7.4 million for the quarter, marking the strongest result in any quarter for the business [8][10] - For FY25, the company generated a positive operating cash flow of AUD 5.8 million, a significant improvement compared to the negative operating cash flow of AUD 7.1 million in FY24 [10] - The EBITDA guidance for FY25 was upgraded to exceed AUD 4.5 million, indicating strong financial performance [5][15] Business Line Data and Key Metrics Changes - The company achieved new sales with a combined total contract value (TCV) of AUD 6.7 million in Q4, with approximately 73% being recurring product revenues [6][7] - The total TCV sales for FY25 reached AUD 73.8 million, representing a 109% increase compared to the prior calendar period, marking a record for the business [6][7] Market Data and Key Metrics Changes - The company noted significant sales activity in Q4, with ongoing positive market opportunities, particularly in the UK and Australia [20][24] - There is an increasing demand for technology to assist with patient flow and hospital in the home solutions, indicating a favorable market environment for the company's offerings [24][31] Company Strategy and Development Direction - The company is focused on expanding its customer base and enhancing existing customer relationships through contract expansions and upselling new modules [4][15] - The strategic emphasis is on addressing the challenges faced by healthcare systems globally, particularly as populations age and healthcare demands increase [5][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's unique solutions to tackle healthcare challenges and the ability to grow and expand capabilities with customers [5][15] - The company anticipates continued positive activity in the market, with a solid pipeline of implementation projects and new sales opportunities [16][20] Other Important Information - The company has no debt and reported cash reserves of AUD 17.7 million as of June 30 [10] - The implementation phase for significant contracts, such as North Cumbria, is progressing well, with expectations for completion in approximately 18 months [12][16] Q&A Session Summary Question: Update on Hume, Nalan, and Bayside sales - Management indicated significant sales in Q4 but noted that not all sales are individually announceable due to ASX regulations [18][19] Question: Tender opportunities in the UK - There is ongoing tender activity in the UK, with the company actively bidding where it has a competitive edge [21][22] Question: Delays in UK implementations - Delays in UHS deployment are primarily due to the transition from one system to another, while Tameside's delays are due to resource constraints on their end [25][26] Question: Revenue composition and cost base - Implementation revenue constitutes 27% of Q4 new sales, with around 15% of the staff working directly on delivery projects [27][28] Question: Update on US partnership with Genie Solaire - The partnership is focused on a go-to-market strategy for the Middle East, with potential US opportunities being explored [28] Question: Impact of NHS digital health funding - There is a continued commitment to digitization in the NHS, with tenders still coming to market [29] Question: Increased spending on enterprise health tech in Australia - There is an uptick in investment in digital health solutions in Australia, particularly in WA and Tasmania [31][32] Question: Upfront capital license receipts for North Cumbria - The upfront capital license receipt for North Cumbria is approximately AUD 8 million, received in the quarter [33] Question: Status of NHS trust APR decisions - The status of APR decisions is not known until the company is informed of being a preferred provider [35] Question: Revenue reliance on the UK and Australia - The company has a balanced revenue stream from the UK and ANZ, while exploring opportunities in Canada, the Middle East, and Southeast Asia [42][43]

Core Insights - Hims & Hers Health, Inc. has made significant progress in international expansion, highlighted by the acquisition of ZAVA, a European digital health platform, which provides access to over 1.3 million active customers and nearly 2.3 million consultations in 2024 [1][7] - The company plans to enter the Canadian market, offering a low-cost weight loss program coinciding with the global launch of generic semaglutide, targeting the obesity treatment market [2][7] - Hims & Hers is transitioning from a U.S.-centric platform to a global digital health leader through strategic acquisitions and localized care delivery [3][7] Financial Performance - Hims & Hers shares have increased by 96.8% year to date, outperforming the industry growth of 6.2% [6] - The Zacks Consensus Estimate for Hims & Hers' 2025 earnings per share indicates a 177.8% improvement from 2024 [8] Valuation Metrics - Hims & Hers has a forward 12-month price-to-sales (P/S) ratio of 4.1X, which is lower than the industry's average of 5.5X but higher than its three-year median of 2.3X [10] - The company currently holds a Zacks Rank 1 (Strong Buy) [12]

ATLANTA, July 21, 2025 (GLOBE NEWSWIRE) -- Sharecare, the health tech company that helps to improve care quality, drive better outcomes, and lower costs across the healthcare ecosystem, today announced a new patient education destination that empowers people to better understand health conditions and take meaningful action towards improved health and well-being: Condition Masterclass. Designed to support patients and their loved ones through complex care journeys, Sharecare’s newest innovative health educat ...

Core Viewpoint - Profusa, Inc. is initiating a Bitcoin treasury strategy through a Securities Purchase Agreement with Ascent Partners Fund LLC, aiming to purchase up to $100,000,000 of the Company's Common Stock, with all net proceeds allocated for Bitcoin purchases [1][6]. Group 1: Treasury Strategy - The Company will execute the strategy under an Equity Line of Credit (ELOC), allowing it to sell shares to Ascent at 97% of the lowest volume-weighted average price in the preceding five trading days [2][4]. - If the cash balance is below $5,000,000 at the time of a put, proceeds will first be used to reach that cash balance before purchasing Bitcoin [3][6]. - The ELOC is subject to customary closing conditions and will initially limit share issuance to 19.9% of the outstanding shares until shareholder approval is obtained [4]. Group 2: Financial Implications - The Company plans to issue cashless warrants to Ascent for 900,000 shares at an exercise price of $0.01 per share [5]. - The first Bitcoin purchases are anticipated to occur within the week, with holdings disclosed quarterly as part of standard financial reporting [7]. Group 3: Strategic Rationale - The CEO emphasized that holding Bitcoin is a strategic move to safeguard shareholder value amid monetary debasement, aligning with a digital future and potentially enhancing shareholder returns [6].

Scryb Appoints Daniel M. Proska as President Forward-Looking Information Cautionary Statement The Company also announces that the Interim CEO, James Van Staveren, has been appointed permanent CEO effective immediately. Mr. Van Staveren has served as the interim CEO since December 2024. About Daniel Proska1 For the majority of his career, Mr.Proska has focused on scaling technology-driven companies, building high performance teams and securing growth capital. He has served on boards of both public and privat ...